Use of evolocumab in a patient with homozygous familial hypercholesterolemia

Introduction: Homozygous familial hypercholesterolemia (FH) is a rare (1:160.000-360.000) but serious disorder with a substantial reduction in low-density lipoprotein receptor (LDLR) function, severely elevated low-density lipoprotein cholesterol (LDL-C), cardiovascular disease, and often death in early decades of life. Response to conventional lipid-lowering agents is modest. Novel monoclonal antibodies to proprotein convertase subtilisin/kexin 9 (PCSK9) have shown ability to substantially reduce LDL-C in heterozygous familial hypercholesterolemia.

Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - December 31, 2016 Category: Nutrition Authors: C. Trenti, E.A. Negri, M.C. Leone, A. Muoio, D. Galimberti, T.A. Pertinhez, D. Farioli, N. Romano, R. Baricchi, L. Vecchia, C. Rabacchi, S. Calandra, T. Fasano Source Type: research